These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 822863)

  • 41. Effect of adherence on antimicrobial susceptibility of Pseudomonas aeruginosa, Serratia marcescens, and Proteus mirabilis.
    Fujiwara S; Miyake Y; Usui T; Suginaka H
    Hiroshima J Med Sci; 1998 Mar; 47(1):1-5. PubMed ID: 9583277
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of elastase, protease and common antigen (OEP) from Pseudomonas aeruginosa on protection against burns in mice.
    Kawaharajo K; Homma JY
    Jpn J Exp Med; 1977 Dec; 47(6):495-500. PubMed ID: 416253
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Specific immune preparations for the prevention and treatment of suppurative-inflammatory diseases of Proteus etiology (a review of the literature)].
    Nazarchuk LV
    Lik Sprava; 1992 Jun; (6):28-34. PubMed ID: 1280887
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of ribosomal preparations from Pseudomonas aeruginosa to protect against intravenous Pseudomonas challenge in mice.
    Smith RL; Wysocki JA; Bruun JN; De Courcy SJ; Blakemore WS; Mudd S
    J Reticuloendothel Soc; 1974 Jan; 15(1):22-30. PubMed ID: 4204145
    [No Abstract]   [Full Text] [Related]  

  • 45. Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection.
    Preston MJ; Gerçeker AA; Koles NL; Pollack M; Pier GB
    Invest Ophthalmol Vis Sci; 1997 Jun; 38(7):1418-25. PubMed ID: 9191605
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immune enhancement of pulmonary bactericidal activity in murine virus pneumonia.
    Jakab GJ; Green GM
    J Clin Invest; 1973 Nov; 52(11):2878-84. PubMed ID: 4356001
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immune enhancement of Taishan Robinia pseudoacacia polysaccharide on recombinant Proteus mirabilis OmpA in chickens.
    Zhang Y; Yang S; Zhao X; Yang Y; Li B; Zhu F; Zhu R
    Int Immunopharmacol; 2014 Sep; 22(1):236-41. PubMed ID: 25000334
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Combined Staphylococcus-Proteus-Pseudomonas vaccine. II. The toxicity of the vaccine in "chronic" experiments and its ability to protect animals against Proteus and Staphylococcus infections].
    Kreĭnin LS; Egorova NB; Stanislavskiĭ ES; Kaverina KG; Levina LA
    Zh Mikrobiol Epidemiol Immunobiol; 1983 May; (5):87-92. PubMed ID: 6410625
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serum immunoglobulin response and protection from homologous challenge by Proteus mirabilis in a mouse model of ascending urinary tract infection.
    Johnson DE; Bahrani FK; Lockatell CV; Drachenberg CB; Hebel JR; Belas R; Warren JW; Mobley HL
    Infect Immun; 1999 Dec; 67(12):6683-7. PubMed ID: 10569791
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Protection against experimental Proteus mirabilis pyelonephritis in rats and significance of immunity.
    Larsson P; Kaijser B; Olling S; Akerlund AS
    Acta Pathol Microbiol Scand C; 1978 Oct; 86C(5):215-20. PubMed ID: 31056
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A new polyvalent Pseudomonas vaccine.
    Miler JM; Spilsbury JF; Jones RJ; Roe EA; Lowbury EJ
    J Med Microbiol; 1977 Feb; 10(1):19-27. PubMed ID: 402473
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cross-protection against Salmonella enteritidis infection in mice.
    Collins FM
    J Bacteriol; 1968 Apr; 95(4):1343-9. PubMed ID: 4967195
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Obtaining antisera to Pseudomonas aeruginosa and Proteus antigens for performing immunoenzyme analyses in clinical practice].
    Bulava GV; Ermolin GA
    Zh Mikrobiol Epidemiol Immunobiol; 1985 Jan; (1):51-5. PubMed ID: 3920845
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Early protection by vaccines in burns.
    Jones RJ
    Br J Exp Pathol; 1971 Feb; 52(1):100-9. PubMed ID: 4993954
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The immunogenicity of mono- and associated vaccines made from strains of opportunistic bacteria].
    Soboleva SV
    Zh Mikrobiol Epidemiol Immunobiol; 1991 Oct; (10):31-4. PubMed ID: 1801485
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Monoclonal antibody-mediated protection and neutralization of motility in experimental Proteus mirabilis infection.
    Harmon RC; Rutherford RL; Wu HM; Collins MS
    Infect Immun; 1989 Jul; 57(7):1936-41. PubMed ID: 2659528
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vaccines in prophylaxis of urinary tract infections caused by the bacteria from the genus Proteus.
    Drzewiecka D; Lewandowska G
    Postepy Hig Med Dosw (Online); 2016 Sep; 70(0):1032-1043. PubMed ID: 27708208
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vaccination against 77 capsular types of Klebsiella aerogenes with polyvalent Klebsiella vaccines.
    Jones RJ; Roe EA
    J Med Microbiol; 1984 Dec; 18(3):413-21. PubMed ID: 6389878
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Detection and study of the labile toxic factor of Proteus mirabilis].
    Efimov GE
    Zh Mikrobiol Epidemiol Immunobiol; 1979 Jan; (1):69-74. PubMed ID: 371267
    [TBL] [Abstract][Full Text] [Related]  

  • 60. THE FATE OF PSEUDOMONAS AERUGINOSA, PROTEUS MIRABILIS AND ESCHERICHIA COLI IN THE MOUSE KIDNEY.
    GORRILL RH
    J Pathol Bacteriol; 1965 Jan; 89():81-8. PubMed ID: 14263500
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.